Czeizel A E, Rockenbauer M
Department of Human Genetics and Teratology, National Institute of Hygiene--World Health Organization Collaborating Centre for the Community Control of Hereditary Diseases, Budapest, Hungary.
Obstet Gynecol. 1997 Apr;89(4):524-8. doi: 10.1016/S0029-7844(97)00005-7.
To study the human teratogenic risk of doxycycline treatment during pregnancy.
Paired analysis of cases with congenital abnormalities and matched healthy controls was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1992.
Of 32,804 pregnant women who had infants with no defects in the study period (control group), 63 (0.19%) were treated with doxycycline. Of 18,515 pregnant women who had offspring with congenital abnormalities, 56 (0.30%) were treated with doxycycline, a rate that is higher than that of the control group (P = .01). However, the case-control pair analysis did not show a significantly higher rate of doxycycline treatment in the second and third months of gestation in any group of congenital abnormalities.
Treatment with doxycycline during pregnancy presents very little if any teratogenic risk to the fetus. Thus, if doxycycline treatment is necessary during pregnancy, there would appear to be no contraindication.
研究孕期使用强力霉素治疗对人类的致畸风险。
在1980 - 1992年匈牙利先天性异常病例对照监测的大型人群数据集里，对先天性异常病例与匹配的健康对照进行配对分析。
在研究期间生育无缺陷婴儿的32,804名孕妇（对照组）中，63名（0.19%）接受了强力霉素治疗。在生育有先天性异常后代的18,515名孕妇中，56名（0.30%）接受了强力霉素治疗，该比例高于对照组（P = 0.01）。然而，病例对照配对分析并未显示在任何先天性异常组中，妊娠第二和第三个月使用强力霉素治疗的比例显著更高。
孕期使用强力霉素对胎儿的致畸风险极小（如果有的话）。因此，如果孕期有必要使用强力霉素治疗，似乎没有禁忌证。
